Longitudinal analysis of endurance and respiratory function from a natural history study of Morquio A syndrome. (Q41590797)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25582974%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

title

Longitudinal analysis of endurance and respiratory function from a natural history study of Morquio A syndrome (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25582974%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25582974%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

Chris Hendriksz

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25582974%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

John J. Mitchell

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25582974%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

3

Roberto Giugliani

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25582974%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

author name string

Paul R Harmatz

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25582974%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

Karl Eugen Mengel

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25582974%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

Shuan-Pei Lin

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25582974%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

Nathalie Guffon

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25582974%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

Barbara K Burton

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25582974%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

Ana Maria Martins

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25582974%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

Simon A Jones

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25582974%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

Norberto Guelbert

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25582974%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

Ashok Vellodi

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25582974%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

Frits A Wijburg

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25582974%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

Ke Yang

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25582974%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

Peter Slasor

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25582974%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

Celeste Decker

18

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25582974%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

Vassili Valayannopoulos

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25582974%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

language of work or name

1 reference

1 November 2014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25582974%20AND%20SRC:MED&resulttype=core&format=json

Molecular Genetics and Metabolism

27 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25582974%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

volume

114

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25582974%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

page(s)

186-194

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25582974%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25582974%20AND%20SRC:MED&resulttype=core&format=json

International Morquio A Registry: clinical manifestation and natural course of Morquio A disease.

27 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2014.10.015

The Morquio A Clinical Assessment Program: baseline results illustrating progressive, multisystemic clinical impairments in Morquio A subjects.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2014.10.015

Clinical overview and treatment options for non-skeletal manifestations of mucopolysaccharidosis type IVA

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2014.10.015

Mucopolysaccharidosis type IVA (Morquio A disease): clinical review and current treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2014.10.015

Review of clinical presentation and diagnosis of mucopolysaccharidosis IVA

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2014.10.015

Spinal involvement in mucopolysaccharidosis IVA (Morquio-Brailsford or Morquio A syndrome): presentation, diagnosis and management.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2014.10.015

Orthopedic management of the extremities in patients with Morquio A syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2014.10.015

Mutation and polymorphism spectrum of the GALNS gene in mucopolysaccharidosis IVA (Morquio A).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2014.10.015

Mucopolysaccharidosis IVA: correlation between genotype, phenotype and keratan sulfate levels

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2014.10.015

Natural history and clinical assessment of Taiwanese patients with mucopolysaccharidosis IVA.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2014.10.015

Molecular testing of 163 patients with Morquio A (Mucopolysaccharidosis IVA) identifies 39 novel GALNS mutations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2014.10.015

Mortality in patients with morquio syndrome a.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2014.10.015

Clinical utility of endurance measures for evaluation of treatment in patients with mucopolysaccharidosis VI (Maroteaux-Lamy syndrome).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2014.10.015

Enzyme replacement therapy for mucopolysaccharidosis I: a randomized, double-blinded, placebo-controlled, multinational study of recombinant human alpha-L-iduronidase (laronidase).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2014.10.015

A phase II/III clinical study of enzyme replacement therapy with idursulfase in mucopolysaccharidosis II (Hunter syndrome)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2014.10.015

Enzyme replacement therapy in mucopolysaccharidosis VI (Maroteaux-Lamy syndrome).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2014.10.015

Enzyme replacement therapy for mucopolysaccharidosis VI: A phase 3, randomized, double-blind, placebo-controlled, multinational study of recombinant human N-acetylgalactosamine 4-sulfatase (recombinant human arylsulfatase B or rhASB) and follow-on, o

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2014.10.015

Enzyme replacement therapy for mucopolysaccharidosis VI: evaluation of long-term pulmonary function in patients treated with recombinant human N-acetylgalactosamine 4-sulfatase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2014.10.015

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2014.10.015

Direct comparison of measures of endurance, mobility, and joint function during enzyme-replacement therapy of mucopolysaccharidosis VI (Maroteaux-Lamy syndrome): results after 48 weeks in a phase 2 open-label clinical study of recombinant human N-ac

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2014.10.015

Six-minute walk test in children and adolescents.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2014.10.015

The 6-minute walk test: normal values for children of 4-11 years of age

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2014.10.015

Standard reference for the six-minute-walk test in healthy children aged 7 to 16 years.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2014.10.015

Reference values for the 6-minute walk test in healthy children and adolescents in Switzerland.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2014.10.015

Reference values for the 6-min walk test in healthy subjects 20-50 years old.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2014.10.015

Threshold effect of urinary glycosaminoglycans and the walk test as indicators of disease progression in a survey of subjects with Mucopolysaccharidosis VI (Maroteaux-Lamy syndrome)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2014.10.015

Burden of disease in patients with Morquio A syndrome: results from an international patient-reported outcomes survey

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2014.10.015

Characterization of pulmonary function impairments in patients with mucopolysaccharidoses--changes with age and treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2014.10.015

Lung function in white children aged 4 to 19 years: I--Spirometry

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2014.10.015

Spirometric reference values from a sample of the general U.S. population

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2014.10.015

Spirometric studies on normal subjects. IV. Ventilatory capacities in healthy children 7-17 years of age

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2014.10.015

Respiratory and sleep disorders in mucopolysaccharidosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2014.10.015